Similar articles

• Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.

  Sforzini S, de Totero D, Gaggero A, Ippoliti R, Glennie MJ, Canevari S, Stein H, Ferrini S. Sforzini S, et al. Br J Haematol. 1998 Sep;102(4):1061-8. doi: 10.1046/j.1365-2141.1998.00859.x. Br J Haematol. 1998. PMID: 9734659
• Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.

  Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L, et al. Tazzari PL, et al. Br J Haematol. 1992 Jun;81(2):203-11. doi: 10.1111/j.1365-2141.1992.tb08208.x. Br J Haematol. 1992. PMID: 1322690
• Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.

  Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B. Terenzi A, et al. Br J Haematol. 1996 Mar;92(4):872-9. doi: 10.1046/j.1365-2141.1995.404942.x. Br J Haematol. 1996. PMID: 8616080
• Saporin immunotoxins.

  Flavell DJ. Flavell DJ. Curr Top Microbiol Immunol. 1998;234:57-61. doi: 10.1007/978-3-642-72153-3_4. Curr Top Microbiol Immunol. 1998. PMID: 9670612 Review. No abstract available.
• Hodgkin's disease. Future treatment strategies: fact or fiction?

  Schnell R, Barth S, Diehl V, Engert A. Schnell R, et al. Baillieres Clin Haematol. 1996 Sep;9(3):573-93. doi: 10.1016/s0950-3536(96)80028-x. Baillieres Clin Haematol. 1996. PMID: 8922247 Review.